Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S. Davids, Jennifer R. Brown, David C. Fisher et al.|The Lancet Oncology|2021Cited by 102
Venetoclax plus dose-adjusted R-EPOCH for Richter syndromeMatthew S. Davids, Jennifer R. Brown, Kerry A. Rogers et al.|Blood|2021Cited by 75
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samplesJasneet Kaur Khalsa, Jennifer R. Brown, Justin Cha et al.|Blood|2023Cited by 26
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemiaDeepti Gadi, Jennifer R. Brown, Alec Griffith et al.|Leukemia|2021Cited by 20
Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's SyndromeJennifer L. Crombie, Matthew S. Davids, Svitlana Tyekucheva et al.|Blood|2020Cited by 14